Erratum to

Introduction: There is little evidence available on the efficacy and safety of biologic therapies for the treatment of psoriasis in Hispanic patients. Secukinumab is demonstrated to be highly effective for clearing psoriasis. The aim of this study was to compare the efficacy and safety of secukinuma...

Descripción completa

Detalles Bibliográficos
Autores: Adsit, Sandra, Zaldivar, Enrique Rivas, Sofen, Howard, Dei-Cas, Ignacio, Maldonado-García, César, Peñaranda, Elkin O., Puig Sanz, Lluís|||0000-0001-6083-0952, Meng, Xiangyi, Fox, Todd, Guana, Adriana
Tipo de recurso: artículo
Fecha de publicación:2017
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:186262
Acceso en línea:https://ddd.uab.cat/record/186262
https://dx.doi.org/urn:doi:10.1007/s12325-017-0563-2
Access Level:acceso abierto
Palabra clave:Biologic therapy
Dermatology Life Quality Index
Hispanic
IL-17
Moderate-to-severe psoriasis
Non-Hispanic
Pooled analysis
Psoriasis Area and Severity Index
Secukinumab
Subcutaneous injection
id ES_836151ca1c8e78c2cfaab4c7cb6f4c4f
oai_identifier_str oai:ddd.uab.cat:186262
network_acronym_str ES
network_name_str España
repository_id_str
spelling Erratum toSecukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 TrialsAdsit, SandraZaldivar, Enrique RivasSofen, HowardDei-Cas, IgnacioMaldonado-García, CésarPeñaranda, Elkin O.Puig Sanz, Lluís|||0000-0001-6083-0952Meng, XiangyiFox, ToddGuana, AdrianaBiologic therapyDermatology Life Quality IndexHispanicIL-17Moderate-to-severe psoriasisNon-HispanicPooled analysisPsoriasis Area and Severity IndexSecukinumabSubcutaneous injectionIntroduction: There is little evidence available on the efficacy and safety of biologic therapies for the treatment of psoriasis in Hispanic patients. Secukinumab is demonstrated to be highly effective for clearing psoriasis. The aim of this study was to compare the efficacy and safety of secukinumab in Hispanic and non-Hispanic patients. Methods: Data were pooled from four phase 3 studies of secukinumab in patients with moderate-to-severe plaque psoriasis. Patients who self-identified as Hispanic were included in the Hispanic subgroup.Results: Efficacy responses (Psoriasis Area and Severity Index [PASI] 75/90/100 and Investigator's Global Assessment 2011 modified version 0/1) for secukinumab 300 mg were greater than for etanercept at week 12 in the Hispanic and non-Hispanic patient subgroups. At week 12 with secukinumab 300 mg, PASI 90/100 responses were achieved by 70.6%/35.9% of Hispanic patients and 58.0%/28.1% of non-Hispanic patients. At week 12 with secukinumab 150 mg, PASI 90/100 responses were achieved by 59.5%/25.1% of Hispanic patients and 41.2%/13.4% of non-Hispanic patients. In both subgroups, peak efficacy responses with secukinumab were observed at week 16 and were maintained to week 52.Conclusions: Secukinumab is highly effective for clearing psoriasis in both Hispanic and non-Hispanic patients.Funding: Novartis Pharmaceutical Corporation.Universitat Autònoma de Barcelona 22017-01-0120172017-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/186262https://dx.doi.org/urn:doi:10.1007/s12325-017-0563-2reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:1862622026-06-06T12:50:31Z
dc.title.none.fl_str_mv Erratum to
Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
title Erratum to
spellingShingle Erratum to
Adsit, Sandra
Biologic therapy
Dermatology Life Quality Index
Hispanic
IL-17
Moderate-to-severe psoriasis
Non-Hispanic
Pooled analysis
Psoriasis Area and Severity Index
Secukinumab
Subcutaneous injection
title_short Erratum to
title_full Erratum to
title_fullStr Erratum to
title_full_unstemmed Erratum to
title_sort Erratum to
dc.creator.none.fl_str_mv Adsit, Sandra
Zaldivar, Enrique Rivas
Sofen, Howard
Dei-Cas, Ignacio
Maldonado-García, César
Peñaranda, Elkin O.
Puig Sanz, Lluís|||0000-0001-6083-0952
Meng, Xiangyi
Fox, Todd
Guana, Adriana
author Adsit, Sandra
author_facet Adsit, Sandra
Zaldivar, Enrique Rivas
Sofen, Howard
Dei-Cas, Ignacio
Maldonado-García, César
Peñaranda, Elkin O.
Puig Sanz, Lluís|||0000-0001-6083-0952
Meng, Xiangyi
Fox, Todd
Guana, Adriana
author_role author
author2 Zaldivar, Enrique Rivas
Sofen, Howard
Dei-Cas, Ignacio
Maldonado-García, César
Peñaranda, Elkin O.
Puig Sanz, Lluís|||0000-0001-6083-0952
Meng, Xiangyi
Fox, Todd
Guana, Adriana
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Biologic therapy
Dermatology Life Quality Index
Hispanic
IL-17
Moderate-to-severe psoriasis
Non-Hispanic
Pooled analysis
Psoriasis Area and Severity Index
Secukinumab
Subcutaneous injection
topic Biologic therapy
Dermatology Life Quality Index
Hispanic
IL-17
Moderate-to-severe psoriasis
Non-Hispanic
Pooled analysis
Psoriasis Area and Severity Index
Secukinumab
Subcutaneous injection
description Introduction: There is little evidence available on the efficacy and safety of biologic therapies for the treatment of psoriasis in Hispanic patients. Secukinumab is demonstrated to be highly effective for clearing psoriasis. The aim of this study was to compare the efficacy and safety of secukinumab in Hispanic and non-Hispanic patients. Methods: Data were pooled from four phase 3 studies of secukinumab in patients with moderate-to-severe plaque psoriasis. Patients who self-identified as Hispanic were included in the Hispanic subgroup.Results: Efficacy responses (Psoriasis Area and Severity Index [PASI] 75/90/100 and Investigator's Global Assessment 2011 modified version 0/1) for secukinumab 300 mg were greater than for etanercept at week 12 in the Hispanic and non-Hispanic patient subgroups. At week 12 with secukinumab 300 mg, PASI 90/100 responses were achieved by 70.6%/35.9% of Hispanic patients and 58.0%/28.1% of non-Hispanic patients. At week 12 with secukinumab 150 mg, PASI 90/100 responses were achieved by 59.5%/25.1% of Hispanic patients and 41.2%/13.4% of non-Hispanic patients. In both subgroups, peak efficacy responses with secukinumab were observed at week 16 and were maintained to week 52.Conclusions: Secukinumab is highly effective for clearing psoriasis in both Hispanic and non-Hispanic patients.Funding: Novartis Pharmaceutical Corporation.
publishDate 2017
dc.date.none.fl_str_mv 2
2017-01-01
2017
2017-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/186262
https://dx.doi.org/urn:doi:10.1007/s12325-017-0563-2
url https://ddd.uab.cat/record/186262
https://dx.doi.org/urn:doi:10.1007/s12325-017-0563-2
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412131178283008
score 15.300724

Similares en LA Referencia